Takeda Pharmaceutical Company Limited (TAK)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
Pre-Market:
| Previous Close | 13.28 |
| Open | 13.07 |
| Bid | 12.92 x 4000 |
| Ask | 13.17 x 4000 |
| Day's Range | 13.05 - 13.13 |
| 52 Week Range | 13.01 - 16.69 |
| Volume | |
| Avg. Volume | 1,647,091 |
| Market Cap | 41.089B |
| Beta (5Y Monthly) | 0.54 |
| PE Ratio (TTM) | 36.28 |
| EPS (TTM) | 0.36 |
| Earnings Date | May 09, 2024 |
| Forward Dividend & Yield | 0.64 (4.89%) |
| Ex-Dividend Date | Sept 28, 2023 |
| 1y Target Est | 18.26 |
Business WireTakeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion
OSAKA, Japan, May 09, 2024--Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for fiscal year 2023 (period ended March 31, 2024), delivering its Management Guidance for Core Operating Profit and exceeding its Management Guidance for Revenue and Core EPS performance at CER, in a year of significant loss-of-exclusivity impact.
GuruFocus.comProtagonist Therapeutics Inc (PTGX) Surpasses Q1 Revenue Estimates with Strategic Collaborations
Comprehensive Analysis of Q1 2024 Earnings and Strategic Developments
ZacksDown -6.19% in 4 Weeks, Here's Why Takeda Pharmaceutical Co. (TAK) Looks Ripe for a Turnaround
Takeda Pharmaceutical Co. (TAK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
© 2024 Yahoo. All rights reserved.